Analysis by GlobalData characterises an uncertain pharma landscape, though big pharma CEOs allay investor concern.

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...

July 7 – With a 90-day negotiating period on country-specific US tariffs is set to expire on July 9, Trump enacts a multitude ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient at the ...

The global Plant Derived Proteins Market is on a significant growth trajectory, estimated to reach USD 184.3 Million by 2029, up from USD 105 Million in 2022. This robust expansion, projected at an 8.

Aspiration is terrific, but Labour's bravado about Britain being the fastest growing economy in the G7 was always hooey.

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Colorcon, Inc. (Harleysville, Pa.), a manufacturer of of film coating systems, specialty excipients, controlled release ...

Sen. Tim Kaine has been involved with bringing pharmaceutical reseach and development to central Virginia since his days on ...

AstraZeneca (Cambridge, U.K.) announced $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines ...